{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:29:25Z","timestamp":1794324565116,"version":"4.9.0"},"reference-count":347,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ymgme.2025.109074","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T20:32:18Z","timestamp":1741638738000},"page":"109074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Challenges in Gaucher disease: Perspectives from an expert panel"],"prefix":"10.1016","volume":"145","author":[{"given":"Gregory A.","family":"Grabowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy N.","family":"Alcalay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Grace","family":"Prakalapakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry E.","family":"Rosenbloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick A.","family":"Tuason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal J.","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9645","key":"10.1016\/j.ymgme.2025.109074_bb0005","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher\u2019s disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ymgme.2025.109074_bb0010","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/humu.23611","article-title":"Exploring genetic modifiers of Gaucher disease: the next horizon","volume":"39","author":"Davidson","year":"2018","journal-title":"Hum. Mutat."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ajh.24957","article-title":"Demographics and patient characteristics of 1209 patients with Gaucher disease: descriptive analysis from the Gaucher outcome survey (GOS)","volume":"93","author":"Zimran","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2025.109074_bb0020","first-page":"73","article-title":"Characteristics of 26 patients with type 3 Gaucher disease: a descriptive analysis from the Gaucher outcome survey","volume":"14","author":"Schwartz","year":"2018","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109074_bb0025","series-title":"The Metabolic and Molecular Bases of Inherited Diseases","article-title":"Gaucher disease: Phenotypic and genetic variation","author":"Grabowski","year":"2006"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0030","first-page":"90","article-title":"Recommendations on the follow-up of patients with Gaucher disease in Spain: results from a Delphi survey","volume":"64","author":"Giraldo","year":"2023","journal-title":"JIMD Rep."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0035","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ymgme.2021.12.009","article-title":"Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: results from a Delphi consensus","volume":"135","author":"Kishnani","year":"2022","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109074_bb0040","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/imj.14156","article-title":"Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher earlier diagnosis consensus (GED-C) Delphi initiative","volume":"49","author":"Mehta","year":"2019","journal-title":"Intern. Med. J."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0045","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13312-018-1249-9","article-title":"Diagnosis and Management of Gaucher Disease in India - consensus guidelines of the Gaucher disease task force of the Society for Indian Academy of medical genetics and the Indian academy of pediatrics","volume":"55","author":"Puri","year":"2018","journal-title":"Indian Pediatr."},{"key":"10.1016\/j.ymgme.2025.109074_bb0050","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bcmd.2016.10.008","article-title":"Management goals for type 1 Gaucher disease: an expert consensus document from the European working group on Gaucher disease","volume":"68","author":"Biegstraaten","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2025.109074_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175023","article-title":"Update of treatment for Gaucher disease","volume":"926","author":"Kong","year":"2022","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb0060","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00109-021-02174-z","article-title":"Gaucher disease - more than just a rare lipid storage disease","volume":"100","author":"Roh","year":"2022","journal-title":"J. Mol. Med. (Berl.)"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0065","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2021.01.002","article-title":"Diagnosing neuronopathic Gaucher disease: new considerations and challenges in assigning Gaucher phenotypes","volume":"132","author":"Daykin","year":"2021","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0070","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ymgme.2020.12.291","article-title":"Gaucher disease: basic and translational science needs for more complete therapy and management","volume":"132","author":"Grabowski","year":"2021","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0075","first-page":"7","article-title":"Gaucher disease: new expanded classification emphasizing neurological features","volume":"13","author":"Alaei","year":"2019","journal-title":"Iran J. Child Neurol."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/diseases5010010","article-title":"The Spectrum of neurological manifestations associated with Gaucher disease","volume":"5","author":"Roshan Lal","year":"2017","journal-title":"Diseases"},{"issue":"9","key":"10.1016\/j.ymgme.2025.109074_bb0085","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/1060028013500469","article-title":"Gaucher disease and its treatment options","volume":"47","author":"Bennett","year":"2013","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0090","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3345\/kjp.2012.55.2.48","article-title":"Clinical and genetic characteristics of Gaucher disease according to phenotypic subgroups","volume":"55","author":"Lee","year":"2012","journal-title":"Korean J. Pediatr."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2025.109074_bb0095","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","article-title":"Gaucher disease: complexity in a \u201csimple\u201d disorder","volume":"83","author":"Sidransky","year":"2004","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0100","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1067\/S0022-3476(03)00302-0","article-title":"Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3","volume":"143","author":"Goker-Alpan","year":"2003","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109074_bb0105","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1146\/annurev.genom.4.070802.110415","article-title":"Enzyme therapy for lysosomal storage disease: principles, practice, and prospects","volume":"4","author":"Grabowski","year":"2003","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0110","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000112332","article-title":"Partial enzyme deficiencies: residual activities and the development of neurological disorders","volume":"6","author":"Conzelmann","year":"1983","journal-title":"Dev. Neurosci."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1432-1033.1985.tb08655.x","article-title":"Characterization of human glucosylsphingosine glucosyl hydrolase and comparison with glucosylceramidase","volume":"146","author":"Vaccaro","year":"1985","journal-title":"Eur. J. Biochem."},{"issue":"10","key":"10.1016\/j.ymgme.2025.109074_bb0120","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1177\/2472555217719372","article-title":"Tissue localization of glycosphingolipid accumulation in a Gaucher disease mouse brain by LC-ESI-MS\/MS and high-resolution MALDI imaging mass spectrometry","volume":"22","author":"Jones","year":"2017","journal-title":"SLAS Discov."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109074_bb0125","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0002-9440(10)63566-3","article-title":"Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease","volume":"163","author":"Xu","year":"2003","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0130","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bcmd.2013.03.006","article-title":"Transgenic mice expressing human glucocerebrosidase variants: utility for the study of Gaucher disease","volume":"51","author":"Sanders","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0135","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12881-019-0759-1","article-title":"Gaucher disease: single gene molecular characterization of one-hundred Indian patients reveals novel variants and the most prevalent mutation","volume":"20","author":"Sheth","year":"2019","journal-title":"BMC Med. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0140","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12881-018-0687-5","article-title":"Biochemical and molecular characterization of adult patients with type I Gaucher disease and carrier frequency analysis of Leu444Pro - a common Gaucher disease mutation in India","volume":"19","author":"Sheth","year":"2018","journal-title":"BMC Med. Genet."},{"issue":"7","key":"10.1016\/j.ymgme.2025.109074_bb0145","first-page":"1","article-title":"Egyptian Gaucher disease type 3 patients: a large cohort study spanning two decades","volume":"2","author":"El-Beshlawy","year":"2023","journal-title":"J. Rare Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109074_bb0150","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/jimd.12235","article-title":"The definition of neuronopathic Gaucher disease","volume":"43","author":"Schiffmann","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109074_bb0155","series-title":"GeneReviews\u00ae","article-title":"Gaucher disease","author":"Hughes","year":"2000"},{"issue":"6 Suppl 8","key":"10.1016\/j.ymgme.2025.109074_bb0160","first-page":"1","article-title":"Disease state awareness in Gaucher disease: a Q&A expert roundtable discussion","volume":"10","author":"Mistry","year":"2012","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb0165","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10545-008-0832-y","article-title":"\u2018Non-neuronopathic\u2019 Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature","volume":"31","author":"Biegstraaten","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"issue":"21","key":"10.1016\/j.ymgme.2025.109074_bb0170","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.179126","article-title":"Deletion of Gba in neurons, but not microglia, causes neurodegeneration in a Gaucher mouse model","volume":"9","author":"Duffy","year":"2024","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb0175","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ymgme.2004.04.011","article-title":"Neuropathology provides clues to the pathophysiology of Gaucher disease","volume":"82","author":"Wong","year":"2004","journal-title":"Mol. Genet. Metab."},{"issue":"10","key":"10.1016\/j.ymgme.2025.109074_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23105842","article-title":"Neuropathological features of Gaucher disease and Gaucher disease with parkinsonism","volume":"23","author":"Furderer","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0185","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/brain\/awac379","article-title":"Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial","volume":"146","author":"Schiffmann","year":"2023","journal-title":"Brain"},{"issue":"77","key":"10.1016\/j.ymgme.2025.109074_bb0190","first-page":"273","article-title":"Gaucher disease: insights from a rare Mendelian disorder","volume":"14","author":"Sidransky","year":"2012","journal-title":"Discov. Med."},{"key":"10.1016\/j.ymgme.2025.109074_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104856","article-title":"Exploring the link between GBA1 mutations and dementia with Lewy bodies. A mini-review","volume":"141","author":"Gaubert","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0200","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ymgme.2019.10.006","article-title":"GBA1 mutations: prospects for exosomal biomarkers in alpha-synuclein pathologies","volume":"129","author":"Johnson","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109074_bb0205","first-page":"69","article-title":"Corticobasal syndrome in a man with Gaucher disease type 1: expansion of the understanding of the neurological spectrum","volume":"17","author":"Potnis","year":"2018","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb0210","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1615\/CritRevOncog.2013006060","article-title":"Gaucher disease: a comprehensive review","volume":"18","author":"Rosenbloom","year":"2013","journal-title":"Crit. Rev. Oncog."},{"issue":"15","key":"10.1016\/j.ymgme.2025.109074_bb0215","doi-asserted-by":"crossref","first-page":"e2119","DOI":"10.1212\/WNL.0000000000010605","article-title":"The natural history of type 2 Gaucher disease in the 21st century: a retrospective study","volume":"95","author":"Roshan Lal","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0220","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2022.03.001","article-title":"The diagnosis and management of Gaucher disease in pediatric patients: where do we go from here?","volume":"136","author":"Weinreb","year":"2022","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0225","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.braindev.2022.09.006","article-title":"Perinatal lethal Gaucher disease: a case report and review of literature","volume":"45","author":"Chida","year":"2023","journal-title":"Brain and Development"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0230","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ymgme.2019.05.011","article-title":"Gaucher disease type 3c: new patients with unique presentations and review of the literature","volume":"127","author":"Kurolap","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"24","key":"10.1016\/j.ymgme.2025.109074_bb0235","doi-asserted-by":"crossref","first-page":"e2272","DOI":"10.1212\/WNL.0000000000008618","article-title":"Variation in cognitive function over time in Gaucher disease type 3","volume":"93","author":"Steward","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0240","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s13023-021-02034-6","article-title":"In-depth phenotyping for clinical stratification of Gaucher disease","volume":"16","author":"D\u2019Amore","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109074_bb0245","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum. Mutat."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb0250","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2012.04.024","article-title":"The role of saposin C in Gaucher disease","volume":"106","author":"Tamargo","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109074_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhazmat.2023.133199","article-title":"Targeting progranulin alleviated silica particles-induced pulmonary inflammation and fibrosis via decreasing Il-6 and Tgf-beta1\/Smad","volume":"465","author":"Zhao","year":"2024","journal-title":"J. Hazard. Mater."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0260","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1038\/s41467-023-37454-4","article-title":"Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism","volume":"14","author":"Baden","year":"2023","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.ymgme.2025.109074_bb0265","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1212\/WNL.0b013e3181b6bb95","article-title":"Systemic inflammation and disease progression in Alzheimer disease","volume":"73","author":"Holmes","year":"2009","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb0270","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2014.38","article-title":"Microglial priming in neurodegenerative disease","volume":"10","author":"Perry","year":"2014","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0275","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/(SICI)1096-8628(19970711)71:1<16::AID-AJMG3>3.0.CO;2-O","article-title":"Gaucher disease: enzyme therapy in the acute neuronopathic variant","volume":"71","author":"Prows","year":"1997","journal-title":"Am. J. Med. Genet."},{"issue":"7643","key":"10.1016\/j.ymgme.2025.109074_bb0280","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature21368","article-title":"Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease","volume":"543","author":"Pandey","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb0285","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10545-006-0316-x","article-title":"Homozygosity for the double D409H+H255Q allele in type II Gaucher disease","volume":"29","author":"Michelakakis","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb0290","doi-asserted-by":"crossref","first-page":"E58","DOI":"10.1002\/humu.20776","article-title":"Haplotype analysis suggests a single Balkan origin for the Gaucher disease [D409H;H255Q] double mutant allele","volume":"29","author":"Santamaria","year":"2008","journal-title":"Hum. Mutat."},{"issue":"Suppl Suppl 1","key":"10.1016\/j.ymgme.2025.109074_bb0295","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/jnc.13385","article-title":"The relationship between glucocerebrosidase mutations and Parkinson disease","volume":"139 Suppl 1","author":"Migdalska-Richards","year":"2016","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0300","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ymgme.2014.08.011","article-title":"CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings","volume":"114","author":"Burrow","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0305","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF00293959","article-title":"Late-infantile Gaucher disease in a child with myoclonus and bulbar signs: neuropathological and neurochemical findings","volume":"82","author":"Conradi","year":"1991","journal-title":"Acta Neuropathol."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb0310","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ajh.23118","article-title":"Genome-wide association study of N370S homozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing to extreme phenotypic variation","volume":"87","author":"Zhang","year":"2012","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.ymgme.2025.109074_bb0315","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/qjmed\/hcg097","article-title":"The interleukin-6 promoter polymorphism in Gaucher disease: a new modifier gene?","volume":"96","author":"Altarescu","year":"2003","journal-title":"QJM"},{"issue":"5","key":"10.1016\/j.ymgme.2025.109074_bb0320","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1023\/B:BOLI.0000042983.60840.f3","article-title":"Gaucher disease: variability in phenotype among siblings","volume":"27","author":"Amato","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109074_bb0325","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3389\/fimmu.2017.01613","article-title":"Visceral inflammation and immune activation stress the brain","volume":"8","author":"Holzer","year":"2017","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb0330","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1172\/JCI126078","article-title":"Visceral adipose NLRP3 impairs cognition in obesity via IL-1R1 on CX3CR1+ cells","volume":"130","author":"Guo","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2025.109074_bb0335","article-title":"Neuroinflammation disorders exacerbated by environmental stressors","volume":"100S","author":"O'Callaghan","year":"2019","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.ymgme.2025.109074_bb0340","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/brain\/awq198","article-title":"Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study","volume":"133","author":"Biegstraaten","year":"2010","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0345","doi-asserted-by":"crossref","first-page":"15358","DOI":"10.1038\/s41598-019-51976-2","article-title":"Polyneuropathy in Gaucher disease type 1 and 3 - a descriptive case series","volume":"9","author":"Andreasson","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0350","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13023-017-0700-7","article-title":"Chronic pain in Gaucher disease: skeletal or neuropathic origin?","volume":"12","author":"Devigili","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2025.109074_bb0355","first-page":"S25","article-title":"Gaucher disease and comorbidities: B-cell malignancy and parkinsonism","volume":"90","author":"Cox","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb0360","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1615\/CritRevOncog.2013006145","article-title":"Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism","volume":"18","author":"Mistry","year":"2013","journal-title":"Crit. Rev. Oncog."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb0365","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10545-010-9095-5","article-title":"The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG)","volume":"33","author":"Cherin","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb0370","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s10545-012-9460-7","article-title":"The cognitive profile of type 1 Gaucher disease patients","volume":"35","author":"Biegstraaten","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109074_bb0375","author":"NORD"},{"key":"10.1016\/j.ymgme.2025.109074_bb0380","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3389\/fneur.2017.00295","article-title":"Saccadic impairments in patients with the Norrbottnian form of Gaucher\u2019s disease type 3","volume":"8","author":"Blume","year":"2017","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0385","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s13023-019-1244-9","article-title":"A comprehensive monocentric ophthalmic study with Gaucher disease type 3 patients: vitreoretinal lesions, retinal atrophy and characterization of abnormal saccades","volume":"14","author":"Hopf","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109074_bb0390","series-title":"School of Biological Sciences","article-title":"Neuronopathic Gaucher disease: a clinical study","author":"Donald","year":"2019"},{"issue":"9","key":"10.1016\/j.ymgme.2025.109074_bb0395","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1007\/s00405-023-07900-6","article-title":"Normative values for the video head impulse test in children without otoneurologic symptoms and their evolution across childhood by gender","volume":"280","author":"Rodriguez-Villalba","year":"2023","journal-title":"Eur. Arch. Otorrinolaringol."},{"key":"10.1016\/j.ymgme.2025.109074_bb0400","first-page":"102","article-title":"A low-cost webcam-based eye tracker and saccade measurement system","volume":"14","author":"Aljaafreh","year":"2020","journal-title":"Int J Circuits Syst. Sign. Proc."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb0405","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s10072-012-1155-1","article-title":"Vertical supranuclear gaze palsy in Niemann-pick type C disease","volume":"33","author":"Salsano","year":"2012","journal-title":"Neurol. Sci."},{"issue":"10","key":"10.1016\/j.ymgme.2025.109074_bb0410","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1212\/01.WNL.0000144275.76658.F4","article-title":"Neuro-ophthalmology of late-onset Tay-Sachs disease (LOTS)","volume":"63","author":"Rucker","year":"2004","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb0415","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.anl.2006.11.003","article-title":"Abnormal electronystagmography in rheumatoid arthritis","volume":"34","author":"Yilmaz","year":"2007","journal-title":"Auris Nasus Larynx"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0420","doi-asserted-by":"crossref","first-page":"16837","DOI":"10.1038\/s41598-022-21230-3","article-title":"Minimal hepatic encephalopathy is associated to alterations in eye movements","volume":"12","author":"Casanova-Ferrer","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymgme.2025.109074_bb0425","article-title":"Ocular manifestations of systemic lupus erythematosus: a review of the literature","volume":"2012","author":"Palejwala","year":"2012","journal-title":"Autoimmune Dis."},{"key":"10.1016\/j.ymgme.2025.109074_bb0430","doi-asserted-by":"crossref","unstructured":"J.S. Wang, et al., Gaucher disease type 3c: expanding the clinical spectrum of an ultra-rare disease, JMID Reports (2024 Aug 15);65(5):313-322.","DOI":"10.1002\/jmd2.12440"},{"issue":"12","key":"10.1016\/j.ymgme.2025.109074_bb0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260241","article-title":"New correlations between ocular parameters and disease severity in Spanish patients with Gaucher's disease Type I","volume":"16","author":"Esteban","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb0440","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/bjophthalmol-2018-312846","article-title":"Ophthalmic manifestations of Gaucher disease: the most common lysosomal storage disorder","volume":"103","author":"Winter","year":"2019","journal-title":"Br. J. Ophthalmol."},{"issue":"19","key":"10.1016\/j.ymgme.2025.109074_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197027","article-title":"Macular ganglion cell complex and Peripapillary retinal nerve Fiber layer thinning in patients with Type-1 Gaucher disease","volume":"21","author":"Weill","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.ymgme.2025.109074_bb0450","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1007\/s00415-020-10304-9","article-title":"Central retina changes in Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"268","author":"Huang","year":"2021","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.ymgme.2025.109074_bb0455","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1001\/archopht.122.9.1395","article-title":"Vitreous opacities and retinal vascular abnormalities in Gaucher disease","volume":"122","author":"Shrier","year":"2004","journal-title":"Arch. Ophthalmol."},{"issue":"9","key":"10.1016\/j.ymgme.2025.109074_bb0460","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/pds.1779","article-title":"Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme","volume":"18","author":"Hollak","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ymgme.2025.109074_bb0465","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.684067","article-title":"Next-generation sequencing analysis of GBA1: the challenge of detecting complex recombinant alleles","volume":"12","author":"Woo","year":"2021","journal-title":"Front. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0470","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/s13023-022-02573-6","article-title":"Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1","volume":"17","author":"Dardis","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"issue":"11","key":"10.1016\/j.ymgme.2025.109074_bb0475","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S1474-4422(23)00283-1","article-title":"Identification of genetic risk loci and causal insights associated with Parkinson\u2019s disease in African and African admixed populations: a genome-wide association study","volume":"22","author":"Rizig","year":"2023","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb0480","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ymgme.2011.12.002","article-title":"Is E326K glucocerebrosidase a polymorphic or pathological variant?","volume":"105","author":"Liou","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109074_bb0485","article-title":"The association between E326K of GBA and the risk of Parkinson\u2019s disease","volume":"2018","author":"Huang","year":"2018","journal-title":"Parkinsons Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb0490","doi-asserted-by":"crossref","DOI":"10.3390\/cells8040364","article-title":"GBA, Gaucher disease, and Parkinson\u2019s disease: from genetic to clinic to new therapeutic approaches","volume":"8","author":"Riboldi","year":"2019","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb0495","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ymgme.2019.10.001","article-title":"Revisiting the non-Gaucher-GBA-E326K carrier state: is it sufficient to increase Parkinson\u2019s disease risk?","volume":"128","author":"Goldstein","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb0500","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20043","article-title":"Functional analysis of 13 GBA mutant alleles identified in Gaucher disease patients: pathogenic changes and \u201cmodifier\u201d polymorphisms","volume":"23","author":"Montfort","year":"2004","journal-title":"Hum. Mutat."},{"issue":"16","key":"10.1016\/j.ymgme.2025.109074_bb0505","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1001\/archinternmed.2010.302","article-title":"Type 1 Gaucher disease: significant disease manifestations in \u201casymptomatic\u201d homozygotes","volume":"170","author":"Balwani","year":"2010","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb0510","article-title":"Small RNA-sequencing: approaches and considerations for miRNA analysis","volume":"11","author":"Benesova","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0515","article-title":"MiRNA expression in patients with Gaucher disease treated with enzyme replacement therapy","volume":"11","author":"Pawlinski","year":"2020","journal-title":"Life (Basel)"},{"key":"10.1016\/j.ymgme.2025.109074_bb0520","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cca.2019.08.010","article-title":"Proteogenomics: from next-generation sequencing (NGS) and mass spectrometry-based proteomics to precision medicine","volume":"498","author":"Ang","year":"2019","journal-title":"Clin. Chim. Acta"},{"issue":"5","key":"10.1016\/j.ymgme.2025.109074_bb0525","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11914-023-00840-4","article-title":"Practical compass of single-cell RNA-Seq analysis","volume":"22","author":"Okada","year":"2024","journal-title":"Curr. Osteoporos. Rep."},{"issue":"26","key":"10.1016\/j.ymgme.2025.109074_bb0530","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk1296","article-title":"The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1","volume":"10","author":"Gustavsson","year":"2024","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0535","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40035-020-00226-x","article-title":"Cross-talks among GBA mutations, glucocerebrosidase, and alpha-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review","volume":"10","author":"Behl","year":"2021","journal-title":"Transl. Neurodegener."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb0540","doi-asserted-by":"crossref","first-page":"261","DOI":"10.14802\/jmd.23023","article-title":"GBA1 variants and Parkinson\u2019s disease: paving the way for targeted therapy","volume":"16","author":"Huh","year":"2023","journal-title":"J. Mov. Disord."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0545","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s12864-023-09417-y","article-title":"GBA1 in Parkinson's disease: variant detection and pathogenicity scoring matters","volume":"24","author":"Gabbert","year":"2023","journal-title":"BMC Genomics"},{"issue":"9","key":"10.1016\/j.ymgme.2025.109074_bb0550","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","article-title":"Differential effects of severe vs mild GBA mutations on Parkinson disease","volume":"84","author":"Gan-Or","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb0555","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/mds.29314","article-title":"Classification of GBA1 variants in Parkinson\u2019s disease: the GBA1-PD browser","volume":"38","author":"Parlar","year":"2023","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0560","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41531-023-00595-w","article-title":"Accurate long-read sequencing identified GBA1 as major risk factor in the Luxembourgish Parkinson's study","volume":"9","author":"Pachchek","year":"2023","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.ymgme.2025.109074_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108419","article-title":"Targeting the GBA1 pathway to slow Parkinson disease: insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues","volume":"246","author":"Menozzi","year":"2023","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.ymgme.2025.109074_bb0570","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00702-022-02531-3","article-title":"Glucocerebrosidase mutations and Parkinson disease","volume":"129","author":"Vieira","year":"2022","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"7","key":"10.1016\/j.ymgme.2025.109074_bb0575","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/jnnp-2020-322857","article-title":"Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson\u2019s disease","volume":"91","author":"Stoker","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"13","key":"10.1016\/j.ymgme.2025.109074_bb0580","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25137102","article-title":"GBA1-associated Parkinson\u2019s disease is a distinct entity","volume":"25","author":"Skrahin","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0585","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/mds.25248","article-title":"The glucocerobrosidase E326K variant predisposes to Parkinson\u2019s disease, but does not cause Gaucher\u2019s disease","volume":"28","author":"Duran","year":"2013","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0590","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/path.4227","article-title":"B cell lymphoma and myeloma in murine Gaucher\u2019s disease","volume":"231","author":"Pavlova","year":"2013","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb0595","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1615\/CritRevOncog.2013005921","article-title":"Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher disease who were never treated with enzyme replacement therapy","volume":"18","author":"Weinreb","year":"2013","journal-title":"Crit. Rev. Oncog."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109074_bb0600","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/j.clml.2023.02.004","article-title":"Monoclonal Gammopathy of undetermined significance: a comprehensive review","volume":"23","author":"Kaur","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"11","key":"10.1016\/j.ymgme.2025.109074_bb0605","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.clml.2022.07.001","article-title":"High dimensional immune profiling of smoldering multiple myeloma distinguishes distinct tumor microenvironments","volume":"22","author":"Fernandez","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"10","key":"10.1016\/j.ymgme.2025.109074_bb0610","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ajh.26675","article-title":"Cancer risk and gammopathies in 2 adults with Gaucher disease type 1 in the international Gaucher group Gaucher registry","volume":"97","author":"Rosenbloom","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb0615","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa1508808","article-title":"Clonal immunoglobulin against Lysolipids in the origin of myeloma","volume":"374","author":"Nair","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb0620","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041247","article-title":"Immunoglobulin abnormalities in Gaucher disease: an analysis of 278 patients included in the French Gaucher disease registry","volume":"21","author":"Nguyen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb0625","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal Gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb0630","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ymgme.2020.01.009","article-title":"Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy","volume":"129","author":"Nair","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109074_bb0635","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.smim.2018.02.006","article-title":"An unexpected player in Gaucher disease: the multiple roles of complement in disease development","volume":"37","author":"Pandey","year":"2018","journal-title":"Semin. Immunol."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb0640","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11912-023-01382-9","article-title":"Clonal hematopoiesis of indeterminate potential: current understanding and future directions","volume":"25","author":"Singh","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ymgme.2025.109074_bb0645","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yjmcc.2021.07.004","article-title":"Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease","volume":"161","author":"Marnell","year":"2021","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"10","key":"10.1016\/j.ymgme.2025.109074_bb0650","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ajh.21492","article-title":"Treatment of multiple myeloma in patients with Gaucher disease","volume":"84","author":"Machaczka","year":"2009","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0655","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bcmd.2003.10.007","article-title":"Effect of enzyme replacement therapy on gammopathies in Gaucher disease","volume":"32","author":"Brautbar","year":"2004","journal-title":"Blood Cells Mol. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb0660","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/ajmg.c.31870","article-title":"Outcomes of screening for gammopathies in children and adults with Gaucher disease type 1 in a cohort from Brazil and the United States","volume":"184","author":"Abell","year":"2020","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0665","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/hematology.2020000123","article-title":"A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact","volume":"2020","author":"Zimran","year":"2020","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"7","key":"10.1016\/j.ymgme.2025.109074_bb0670","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/bloodadvances.2023012304","article-title":"Regression of smoldering myeloma with treatment of Gaucher disease","volume":"8","author":"Barley","year":"2024","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb0675","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/practneurol-2020-002837","article-title":"Paraproteinaemic neuropathy: MGUS and beyond","volume":"21","author":"Carroll","year":"2021","journal-title":"Pract. Neurol."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb0680","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061562","article-title":"From biology to treatment of monoclonal Gammopathies of neurological significance","volume":"14","author":"Visentin","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"160","key":"10.1016\/j.ymgme.2025.109074_bb0685","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0363-2020","article-title":"Interstitial lung disease in lysosomal storage disorders","volume":"30","author":"Borie","year":"2021","journal-title":"Eur. Respir. Rev."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb0690","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ymgme.2021.06.009","article-title":"Throwing a spotlight on under-recognized manifestations of Gaucher disease: pulmonary involvement, lymphadenopathy and Gaucheroma","volume":"133","author":"Ramaswami","year":"2021","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb0695","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1590\/0100-3984.2016.0081","article-title":"Pulmonary involvement in Gaucher disease","volume":"50","author":"de Farias","year":"2017","journal-title":"Radiol. Bras."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109074_bb0700","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1034\/j.1399-0004.2003.00060.x","article-title":"Pulmonary involvement in type 1 Gaucher disease: functional and exercise findings in patients with and without clinical interstitial lung disease","volume":"63","author":"Miller","year":"2003","journal-title":"Clin. Genet."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb0705","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S0046-8177(99)90092-8","article-title":"Pulmonary pathology in Gaucher\u2019s disease","volume":"30","author":"Amir","year":"1999","journal-title":"Hum. Pathol."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb0710","article-title":"Lung diseases and rare disorders: is it a lysosomal storage disease? Differential diagnosis, pathogenetic mechanisms and management","volume":"11","author":"Montanari","year":"2024","journal-title":"Children (Basel)"},{"issue":"8","key":"10.1016\/j.ymgme.2025.109074_bb0715","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/qjmed\/94.8.407","article-title":"Lung involvement and enzyme replacement therapy in Gaucher\u2019s disease","volume":"94","author":"Goitein","year":"2001","journal-title":"QJM"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb0720","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10545-011-9313-9","article-title":"Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapy","volume":"34","author":"Lo","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0725","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020441","article-title":"A review of Gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2025.109074_bb0730","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1750-1172-7-77","article-title":"The French Gaucher\u2019s disease registry: clinical characteristics, complications and treatment of 562 patients","volume":"7","author":"Stirnemann","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0735","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1183\/09031936.96.09020340","article-title":"Pulmonary function abnormalities in type I Gaucher disease","volume":"9","author":"Kerem","year":"1996","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0740","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/02724936.1998.11747927","article-title":"Pulmonary involvement of Gaucher\u2019s disease in children: a common presentation in Saudi Arabia","volume":"18","author":"Banjar","year":"1998","journal-title":"Ann. Trop. Paediatr."},{"key":"10.1016\/j.ymgme.2025.109074_bb0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114405","article-title":"N-butyldeoxynojirimycin (miglustat) ameliorates pulmonary fibrosis through inhibition of nuclear translocation of Smad2\/3","volume":"160","author":"Nakamura","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ymgme.2025.109074_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176366","article-title":"Eliglustat exerts anti-fibrotic effects by activating SREBP2 in TGF-beta1-treated myofibroblasts derived from patients with idiopathic pulmonary fibrosis","volume":"966","author":"Kurumiya","year":"2024","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0755","first-page":"S16","article-title":"Lung involvement of Egyptian children with type 1 and 3 Gaucher disease: does enzyme replacement therapy have a role in reversing symptoms, and can it be considered an index of disease severity?","volume":"111","author":"Abdelwahab","year":"2014","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0760","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/ppul.24544","article-title":"Pulmonary manifestations in young Gaucher disease patients: phenotype-genotype correlation and radiological findings","volume":"55","author":"Gawad Tantawy","year":"2020","journal-title":"Pediatr. Pulmonol."},{"issue":"9","key":"10.1016\/j.ymgme.2025.109074_bb0765","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.rmed.2012.06.014","article-title":"Different features of lung involvement in Niemann-pick disease and Gaucher disease","volume":"106","author":"Gulhan","year":"2012","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109074_bb0770","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ana.21491","article-title":"Randomized, controlled trial of miglustat in Gaucher\u2019s disease type 3","volume":"64","author":"Schiffmann","year":"2008","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb0775","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bcmd.2014.05.007","article-title":"Outcome of early-treated type III Gaucher disease patients","volume":"53","author":"Lee","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2025.109074_bb0780","first-page":"54A","article-title":"The frequency and type of lung involvement in patients with Gaucher\u2019s disease","volume":"58","author":"Lee","year":"1988","journal-title":"Lab. Investig."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2025.109074_bb0785","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1096-7192(02)00122-1","article-title":"Pulmonary hypertension in type 1 Gaucher\u2019s disease: genetic and epigenetic determinants of phenotype and response to therapy","volume":"77","author":"Mistry","year":"2002","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109074_bb0790","article-title":"Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy","volume":"20","author":"Beshlawy","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0795","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1399-3046.2005.00251.x","article-title":"Bilateral lung transplant in Gauchers type-1 disease","volume":"9","author":"Rao","year":"2005","journal-title":"Pediatr. Transplant."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0800","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.chest.2015.09.011","article-title":"Lung transplantation in Gaucher disease: a learning lesson in trying to avoid both Scylla and Charybdis","volume":"149","author":"de Boer","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.ymgme.2025.109074_bb0805","article-title":"Lessons from lung transplantation: cause for redefining the pathophysiology of pulmonary hypertension in gaucher disease","volume":"28","author":"Goobie","year":"2019","journal-title":"Respir. Med. Case. Rep."},{"issue":"9","key":"10.1016\/j.ymgme.2025.109074_bb0810","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ajh.24801","article-title":"Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase\/imiglucerase enzyme replacement therapy in the international collaborative Gaucher group (ICGG) Gaucher registry","volume":"92","author":"Mistry","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0815","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13023-023-02828-w","article-title":"A global neuronopathic gaucher disease registry (GARDIAN): a patient-led initiative","volume":"18","author":"Collin-Histed","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"issue":"7","key":"10.1016\/j.ymgme.2025.109074_bb0820","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.gim.2022.03.021","article-title":"A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: one-year results","volume":"24","author":"Wasserstein","year":"2022","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2025.109074_bb0825","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.bcmd.2016.10.018","article-title":"Gaucheromas: when macrophages promote tumor formation and dissemination","volume":"68","author":"Ivanova","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0830","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jpeds.2006.10.062","article-title":"Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy","volume":"150","author":"Burrow","year":"2007","journal-title":"J. Pediatr."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0835","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-0040-1714699","article-title":"Large mesenteric Gaucheroma responds to substrate reduction therapy: a new management of Gaucheromas","volume":"11","author":"Yano","year":"2022","journal-title":"J. Pediatr. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0840","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5334\/jbsr.3184","article-title":"Gaucheroma of mesenteric lymph nodes and their ultrasound appearance: a case report","volume":"107","author":"Saliba","year":"2023","journal-title":"J. Belg. Soc. Radiol."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0845","doi-asserted-by":"crossref","first-page":"86","DOI":"10.15403\/jgld-4752","article-title":"Hepatic, splenic, and bone marrow Gaucheromas: a case series and systematic literature review","volume":"32","author":"Chis","year":"2023","journal-title":"J. Gastrointestin. Liver Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb0850","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/bjh.14915","article-title":"Iron storage in liver, bone marrow and splenic Gaucheroma reflects residual disease in type 1 Gaucher disease patients on treatment","volume":"179","author":"Regenboog","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0855","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jimd.12188","article-title":"Reduction of large soft-tissue Gaucheromas with substrate reduction therapy","volume":"43","author":"Mahajan","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"issue":"44","key":"10.1016\/j.ymgme.2025.109074_bb0860","doi-asserted-by":"crossref","first-page":"18054","DOI":"10.1073\/pnas.1207889109","article-title":"Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease","volume":"109","author":"Panicker","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0865","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/acel.12409","article-title":"Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages","volume":"15","author":"Aflaki","year":"2016","journal-title":"Aging Cell"},{"key":"10.1016\/j.ymgme.2025.109074_bb0870","article-title":"Tissue-resident macrophage development and function","volume":"8","author":"Wu","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0875","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.immuni.2014.06.013","article-title":"Origin and functions of tissue macrophages","volume":"41","author":"Epelman","year":"2014","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0880","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ydbio.2018.07.009","article-title":"The phenotypic and functional properties of mouse yolk-sac-derived embryonic macrophages","volume":"442","author":"Yosef","year":"2018","journal-title":"Dev. Biol."},{"issue":"9","key":"10.1016\/j.ymgme.2025.109074_bb0885","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41577-023-00848-y","article-title":"Tissue-specific macrophages: how they develop and choreograph tissue biology","volume":"23","author":"Mass","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"63","key":"10.1016\/j.ymgme.2025.109074_bb0890","doi-asserted-by":"crossref","first-page":"106171","DOI":"10.18632\/oncotarget.22584","article-title":"Non-classical monocytes in tissue injury and cancer","volume":"8","author":"Bharat","year":"2017","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.ymgme.2025.109074_bb0895","doi-asserted-by":"crossref","first-page":"8767","DOI":"10.1073\/pnas.91.19.8767","article-title":"P-selectin induces the expression of tissue factor on monocytes","volume":"91","author":"Celi","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb0900","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1046\/j.1365-2141.1997.d01-2076.x","article-title":"Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy","volume":"96","author":"Hollak","year":"1997","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb0905","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ajh.10361","article-title":"D-dimer assay in Gaucher disease: correlation with severity of bone and lung involvement","volume":"73","author":"Shitrit","year":"2003","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb0910","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/MBC.0b013e3283424809","article-title":"D-dimer assay in Egyptian patients with Gaucher disease: correlation with bone and lung involvement","volume":"22","author":"Sherif","year":"2011","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.ymgme.2025.109074_bb0915","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2147\/JIR.S292513","article-title":"In vitro phenotype induction of circulating monocytes: CD16 and CD163 analysis","volume":"14","author":"Karsulovic","year":"2021","journal-title":"J. Inflamm. Res."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0920","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.intimp.2014.12.039","article-title":"Macrophage-derived soluble CD163 level in young patients with Gaucher disease: relation to phenotypes, disease severity and complications","volume":"24","author":"Adly","year":"2015","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109074_bb0925","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1182\/blood.2023022522","article-title":"Hot under the clot: venous thrombogenesis is an inflammatory process","volume":"144","author":"Rayes","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2025.109074_bb0930","series-title":"Abstract 1153. in American Society of Hematology Annual Meeting","article-title":"Deciphering inflammasome activation in Gaucher macrophages","author":"Reinecke","year":"2024"},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb0935","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/cdd.2016.24","article-title":"Ly6C(+) monocyte efferocytosis and cross-presentation of cell-associated antigens","volume":"23","author":"Larson","year":"2016","journal-title":"Cell Death Differ."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0940","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.immuni.2017.07.019","article-title":"T cell zone resident macrophages silently dispose of apoptotic cells in the lymph node","volume":"47","author":"Baratin","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.ymgme.2025.109074_bb0945","doi-asserted-by":"crossref","unstructured":"Spector, W.G. and K.M. Wynne, Proliferation of macrophages in inflammation. Agents Actions, 1976. 6(1\u20133): p. 123\u20136.","DOI":"10.1007\/BF01972195"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb0950","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41598-017-00477-1","article-title":"Non-classical monocytes are biased progenitors of wound healing macrophages during soft tissue injury","volume":"7","author":"Olingy","year":"2017","journal-title":"Sci. Rep."},{"issue":"6035","key":"10.1016\/j.ymgme.2025.109074_bb0955","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1126\/science.1204351","article-title":"Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation","volume":"332","author":"Jenkins","year":"2011","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.ymgme.2025.109074_bb0960","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.cmet.2021.10.015","article-title":"Efferocytosis induces macrophage proliferation to help resolve tissue injury","volume":"33","author":"Gerlach","year":"2021","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb0965","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.17338","article-title":"Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations","volume":"194","author":"Rosinol","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb0970","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1128\/IAI.06332-11","article-title":"Analysis of cell cycle and replication of mouse macrophages after in vivo and in vitro Cryptococcus neoformans infection using laser scanning cytometry","volume":"80","author":"Coelho","year":"2012","journal-title":"Infect. Immun."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb0975","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/JLB.3RU1018-378RR","article-title":"M2b macrophage polarization and its roles in diseases","volume":"106","author":"Wang","year":"2019","journal-title":"J. Leukoc. Biol."},{"issue":"45","key":"10.1016\/j.ymgme.2025.109074_bb0980","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.1003308107","article-title":"Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage","volume":"107","author":"Mistry","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2025.109074_bb0985","article-title":"Very rare condition of multiple Gaucheroma: a case report and review of the literature","volume":"20","author":"Tseng","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109074_bb0990","article-title":"Long-term outcomes of disease modifying therapies in Gaucher disease","volume":"5","author":"Manisha","year":"2024","journal-title":"Indian J. Pediatr."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb0995","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cell.2019.10.005","article-title":"Cellular senescence: defining a path forward","volume":"179","author":"Gorgoulis","year":"2019","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb1000","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF00690463","article-title":"Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies","volume":"65","author":"Conradi","year":"1984","journal-title":"Acta Neuropathol."},{"issue":"7","key":"10.1016\/j.ymgme.2025.109074_bb1005","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ajh.21721","article-title":"Hyperferritinemia and iron overload in type 1 Gaucher disease","volume":"85","author":"Stein","year":"2010","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb1010","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202010162","article-title":"Similarities and interplay between senescent cells and macrophages","volume":"220","author":"Behmoaras","year":"2021","journal-title":"J. Cell Biol."},{"issue":"10","key":"10.1016\/j.ymgme.2025.109074_bb1015","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11102623","article-title":"Interleukin-6 in hepatocellular carcinoma: a dualistic point of view","volume":"11","author":"Nenu","year":"2023","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.ymgme.2025.109074_bb1020","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10545-018-0142-y","article-title":"Hepatocellular carcinoma in Gaucher disease: an international case series","volume":"41","author":"Regenboog","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb1025","doi-asserted-by":"crossref","DOI":"10.1088\/1758-5090\/ac6d11","article-title":"Mimicking tumor microenvironment by 3D bioprinting: 3D cancer modeling","volume":"14","author":"Shukla","year":"2022","journal-title":"Biofabrication"},{"key":"10.1016\/j.ymgme.2025.109074_bb1030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bcmd.2016.06.009","article-title":"Imaging characteristics of focal splenic and hepatic lesions in type 1 Gaucher disease","volume":"60","author":"Regenboog","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb1035","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1053\/j.semnuclmed.2017.02.004","article-title":"Benign bone conditions that may be FDG-avid and mimic malignancy","volume":"47","author":"Kwee","year":"2017","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.ymgme.2025.109074_bb1040","first-page":"101","article-title":"Rare case of hepatic Gaucheroma in a child on enzyme replacement therapy","volume":"32","author":"Korula","year":"2017","journal-title":"JIMD Rep."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb1045","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/RLU.0000000000000369","article-title":"Focal splenic FDG uptake in a patient with kala-azar (visceral leishmaniasis)","volume":"39","author":"Fuertes","year":"2014","journal-title":"Clin. Nucl. Med."},{"issue":"12","key":"10.1016\/j.ymgme.2025.109074_bb1050","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1017\/S0022215113002521","article-title":"Middle-ear involvement in type I Gaucher\u2019s disease - a unique case","volume":"127","author":"Khan","year":"2013","journal-title":"J. Laryngol. Otol."},{"key":"10.1016\/j.ymgme.2025.109074_bb1055","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/978-1-0716-2910-9_20","article-title":"Inhibitors of glucosylceramide synthase","volume":"2613","author":"Shayman","year":"2023","journal-title":"Methods Mol. Biol."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb1060","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/jnen\/nlad012","article-title":"Outside the fiber: Endomysial stromal and capillary pathology in skeletal muscle may impede infusion therapy in infantile-onset Pompe disease","volume":"82","author":"Buckley","year":"2023","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb1065","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/1097-0142(20010201)91:3<457::AID-CNCR1022>3.0.CO;2-J","article-title":"Adult Gaucher disease in association with primary malignant bone tumors","volume":"91","author":"Bohm","year":"2001","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb1070","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1258\/smj.2011.011178","article-title":"Synchronous presentation of Gaucher disease and solitary plasmacytoma with progression to multiple myeloma","volume":"56","author":"Hawkesford","year":"2011","journal-title":"Scott. Med. J."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb1075","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ymgme.2020.07.011","article-title":"Unraveling the mystery of Gaucher bone density pathophysiology","volume":"132","author":"Rozenfeld","year":"2021","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb1080","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ymgme.2020.06.003","article-title":"Gaucher disease-associated alterations in mesenchymal stem cells reduce osteogenesis and favour adipogenesis processes with concomitant increased osteoclastogenesis","volume":"130","author":"Crivaro","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"15","key":"10.1016\/j.ymgme.2025.109074_bb1085","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1182\/blood-2009-02-205708","article-title":"Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome","volume":"114","author":"Campeau","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1090","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.212779","article-title":"Radiographic cortical thickness index predicts fragility fracture in Gaucher disease","volume":"307","author":"D\u2019Amore","year":"2023","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb1095","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jbmr.3734","article-title":"Gaucher disease in bone: from pathophysiology to practice","volume":"34","author":"Hughes","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bcmd.2010.10.010","article-title":"Potential biomarkers of osteonecrosis in Gaucher disease","volume":"46","author":"Pavlova","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109074_bb1105","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1182\/blood-2003-11-3854","article-title":"Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy","volume":"104","author":"Wenstrup","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1110","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13244-019-0743-5","article-title":"Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement","volume":"10","author":"Degnan","year":"2019","journal-title":"Insights Imag."},{"issue":"11","key":"10.1016\/j.ymgme.2025.109074_bb1115","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3949\/ccjm.88a.20199","article-title":"DXA and clinical challenges of fracture risk assessment in primary care","volume":"88","author":"Williams","year":"2021","journal-title":"Cleve. Clin. J. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb1120","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00256-007-0425-0","article-title":"Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease","volume":"37","author":"Maas","year":"2008","journal-title":"Skeletal Radiol."},{"issue":"9","key":"10.1016\/j.ymgme.2025.109074_bb1125","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00198-004-1600-y","article-title":"Impact of degenerative spinal diseases on bone mineral density of the lumbar spine in elderly women","volume":"15","author":"Muraki","year":"2004","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb1130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/a-0788-8795","article-title":"Retrospective analysis of whole-body magnetic resonance imaging of bone manifestations in long-term treated patients with Gaucher disease type 1","volume":"231","author":"Lollert","year":"2019","journal-title":"Klin. Padiatr."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb1135","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2214\/ajr.179.4.1790961","article-title":"Quantification of skeletal involvement in adults with type I Gaucher\u2019s disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter","volume":"179","author":"Maas","year":"2002","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.ymgme.2025.109074_bb1140","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.clinimag.2018.06.011","article-title":"Multi-parametric MR imaging using apparent diffusion coefficient and fat fraction in quantification of bone marrow in pediatrics with Gaucher disease","volume":"51","author":"Razek","year":"2018","journal-title":"Clin. Imaging"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb1145","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2292020296","article-title":"Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging--initial experience","volume":"229","author":"Maas","year":"2003","journal-title":"Radiology"},{"key":"10.1016\/j.ymgme.2025.109074_bb1150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinimag.2020.02.009","article-title":"Gaucher disease status and treatment assessment: pilot study using magnetic resonance spectroscopy bone marrow fat fractions in pediatric patients","volume":"63","author":"Degnan","year":"2020","journal-title":"Clin. Imaging"},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb1155","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/RCT.0000000000001452","article-title":"Use of IDEAL-IQ in quantifying femoral bone marrow involvement in Gaucher disease","volume":"47","author":"Hou","year":"2023","journal-title":"J. Comput. Assist. Tomogr."},{"issue":"7","key":"10.1016\/j.ymgme.2025.109074_bb1160","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/imj.15858","article-title":"Fat fraction quantification of bone marrow in the lumbar spine using the LiverLab assessment tool in healthy adult volunteers and patients with Gaucher disease","volume":"53","author":"Gan","year":"2023","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.ymgme.2025.109074_bb1165","article-title":"Bone marrow adipocytes alteration in an in vitro model of Gaucher disease","volume":"36","author":"Crivaro","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"7","key":"10.1016\/j.ymgme.2025.109074_bb1170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069293","article-title":"A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patients","volume":"8","author":"Lecourt","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ymgme.2025.109074_bb1175","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/hmg\/ddu538","article-title":"Glucocerebrosidase deficiency in zebrafish affects primary bone ossification through increased oxidative stress and reduced Wnt\/beta-catenin signaling","volume":"24","author":"Zancan","year":"2015","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb1180","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1023\/A:1011513223894","article-title":"Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis","volume":"2","author":"Justesen","year":"2001","journal-title":"Biogerontology"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1185","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/ncprheum0070","article-title":"Mechanisms of disease: is osteoporosis the obesity of bone?","volume":"2","author":"Rosen","year":"2006","journal-title":"Nat. Clin. Pract. Rheumatol."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb1190","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1210\/jc.2012-3949","article-title":"Vertebral bone marrow fat associated with lower trabecular BMD and prevalent vertebral fracture in older adults","volume":"98","author":"Schwartz","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb1195","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10713","article-title":"A quantification method for disorganized bone components: application to the femoral shaft","volume":"7","author":"Zebaze","year":"2023","journal-title":"JBMR Plus"},{"issue":"8","key":"10.1016\/j.ymgme.2025.109074_bb1200","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/jbmr.3721","article-title":"Adding marrow adiposity and cortical porosity to femoral neck areal bone mineral density improves the discrimination of women with nonvertebral fractures from controls","volume":"34","author":"Zebaze","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1205","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S2213-8587(18)30308-5","article-title":"Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the bone microarchitecture international consortium (BoMIC): a prospective study","volume":"7","author":"Samelson","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1210","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/jbmr.3590","article-title":"Cortical bone material strength index and bone microarchitecture in postmenopausal women with atypical femoral fractures","volume":"34","author":"Popp","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb1215","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jbmr.3078","article-title":"Understanding bone strength is not enough","volume":"32","author":"Hernandez","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ymgme.2025.109074_bb1220","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13023-015-0280-3","article-title":"Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3)","volume":"10","author":"Weinreb","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1225","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ajh.25300","article-title":"Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: final results from the phase 2 trial","volume":"94","author":"Lukina","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"11","key":"10.1016\/j.ymgme.2025.109074_bb1230","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ajh.24877","article-title":"Outcomes after 18 months of eliglustat therapy in treatment-naive adults with Gaucher disease type 1: the phase 3 ENGAGE trial","volume":"92","author":"Mistry","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.ymgme.2025.109074_bb1235","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.clinthera.2007.08.006","article-title":"Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies","volume":"29","author":"Pastores","year":"2007","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb1240","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2214\/AJR.06.1410","article-title":"Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher\u2019s disease using the bone marrow burden score","volume":"188","author":"Robertson","year":"2007","journal-title":"AJR Am. J. Roentgenol."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb1245","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2005-12-5072","article-title":"Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis","volume":"108","author":"de Fost","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ymgme.2025.109074_bb1250","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/ajh.27347","article-title":"Long-term effectiveness of eliglustat treatment: a real-world analysis from the international collaborative Gaucher group Gaucher registry","volume":"99","author":"Mistry","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2025.109074_bb1255","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2021.102591","article-title":"Bone marrow burden score is not useful as a follow-up parameter in stable patients with type 1 Gaucher disease after 5 years of treatment","volume":"90","author":"Paskulin","year":"2021","journal-title":"Blood Cells Mol. Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb1260","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2018.11.004","article-title":"Bone manifestations in neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy","volume":"126","author":"Potnis","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb1265","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jocd.2016.07.003","article-title":"Evaluation of bone mineral density in patients with type 1 Gaucher disease in Argentina","volume":"19","author":"Larroude","year":"2016","journal-title":"J. Clin. Densitom."},{"issue":"7","key":"10.1016\/j.ymgme.2025.109074_bb1270","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3324\/haematol.12651","article-title":"Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy","volume":"93","author":"de Fost","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1275","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcmd.2010.10.011","article-title":"Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults","volume":"46","author":"Mistry","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109074_bb1280","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological Management of Osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1285","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11420-015-9469-1","article-title":"Bisphosphonate treatment in osteoporosis: optimal duration of therapy and the incorporation of a drug holiday","volume":"12","author":"Villa","year":"2016","journal-title":"HSS J."},{"key":"10.1016\/j.ymgme.2025.109074_bb1290","first-page":"23","article-title":"Improvement in bone mineral density and architecture in a patient with Gaucher disease using Teriparatide","volume":"22","author":"Khan","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2025.109074_bb1295","author":"Lilly"},{"issue":"8","key":"10.1016\/j.ymgme.2025.109074_bb1300","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1210\/jc.2008-2630","article-title":"Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis","volume":"94","author":"Leder","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.ymgme.2025.109074_bb1305","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s00198-008-0825-6","article-title":"Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis","volume":"20","author":"Meunier","year":"2009","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb1310","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s00774-020-01176-0","article-title":"Sclerostin: from bench to bedside","volume":"39","author":"Tanaka","year":"2021","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.ymgme.2025.109074_bb1315","author":"Amgen"},{"issue":"7","key":"10.1016\/j.ymgme.2025.109074_bb1320","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1210\/clinem\/dgab193","article-title":"Cardiovascular safety and Sclerostin inhibition","volume":"106","author":"Langdahl","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb1325","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2008.12.001","article-title":"Patients with Gaucher disease living in England show a high prevalence of vitamin D insufficiency with correlation to osteodensitometry","volume":"96","author":"Mikosch","year":"2009","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb1330","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10545-010-9070-1","article-title":"High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease","volume":"33","author":"Taddei","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109074_bb1335","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.2147\/TCRM.S177480","article-title":"Gene variants of osteoprotegerin, estrogen-, calcitonin- and vitamin D-receptor genes and serum markers of bone metabolism in patients with Gaucher disease type 1","volume":"14","author":"Zimmermann","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"issue":"10","key":"10.1016\/j.ymgme.2025.109074_bb1340","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10102217","article-title":"TRAP5b and RANKL\/OPG predict bone pathology in patients with Gaucher disease","volume":"10","author":"Ivanova","year":"2021","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1345","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13023-020-01656-6","article-title":"The international collaborative Gaucher group GRAF (Gaucher risk assessment for fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients","volume":"16","author":"Deegan","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb1350","first-page":"165","article-title":"Gaucher disease: the role of the specialist on metabolic bone diseases","volume":"12","author":"Masi","year":"2015","journal-title":"Clin. Cases Miner. Bone Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1355","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","article-title":"Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy","volume":"90","author":"Deegan","year":"2011","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb1360","first-page":"273","article-title":"Gaucher disease in Latin America. A report from the Gaucher Disease International Registry and the Latin American Group for Gaucher Disease","volume":"72","author":"Drelichman","year":"2012","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.ymgme.2025.109074_bb1365","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2022.102705","article-title":"Long-term bone outcomes in Italian patients with Gaucher disease type 1 or type 3 treated with imiglucerase: a sub-study from the international collaborative Gaucher group (ICGG) Gaucher registry","volume":"98","author":"Cappellini","year":"2023","journal-title":"Blood Cells Mol. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb1370","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1399-0004.2007.00811.x","article-title":"Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease","volume":"71","author":"Weinreb","year":"2007","journal-title":"Clin. Genet."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109074_bb1375","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/MPH.0000000000002249","article-title":"Clinical characteristics, molecular background, and survival of Egyptian patients with Gaucher disease over a 20-year follow-up","volume":"44","author":"El-Beshlawy","year":"2022","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2025.109074_bb1380","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1182\/blood-2022-158444","article-title":"Femur infiltration: a feature that predict bone complications in Gaucher disease. Re-assessing bone marrow involvement through machine learning","volume":"140","author":"Andrade-Campos","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb1385","first-page":"619","article-title":"Posterior spinal fusion for severe kyphosis in a child with Gaucher disease: a case report and review of the literature","volume":"5","author":"Zhao","year":"2024","journal-title":"Res. Square"},{"issue":"3\u20134","key":"10.1016\/j.ymgme.2025.109074_bb1390","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000514507","article-title":"Clinicogenetic profile, treatment modalities, and mortality predictors of Gaucher disease: a 15-year retrospective study","volume":"24","author":"Barney","year":"2021","journal-title":"Public Health Genomics"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb1395","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00007632-199303000-00004","article-title":"Spinal involvement in children and adolescents with Gaucher disease","volume":"18","author":"Katz","year":"1993","journal-title":"Spine (Phila Pa 1976)"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb1400","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01241398-200005000-00022","article-title":"Surgical management of spinal involvement in children and adolescents with Gaucher\u2019s disease","volume":"20","author":"Kocher","year":"2000","journal-title":"J. Pediatr. Orthop."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb1405","doi-asserted-by":"crossref","first-page":"222","DOI":"10.22603\/ssrr.1.2017-0038","article-title":"Corrective surgery for kyphosis in a case of Gaucher's disease without history of vertebral compression fractures","volume":"1","author":"Ito","year":"2017","journal-title":"Spine Surg. Relat. Res."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1410","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13023-022-02378-7","article-title":"Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease","volume":"17","author":"Donald","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb1415","first-page":"158","article-title":"Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and\/or enzyme replacement therapy","volume":"2","author":"Kauli","year":"2000","journal-title":"Isr. Med. Assoc. J."},{"issue":"12","key":"10.1016\/j.ymgme.2025.109074_bb1420","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/0026-0495(89)90165-0","article-title":"Resting energy expenditure in Gaucher\u2019s disease type 1: effect of Gaucher\u2019s cell burden on energy requirements","volume":"38","author":"Barton","year":"1989","journal-title":"Metabolism"},{"key":"10.1016\/j.ymgme.2025.109074_bb1425","article-title":"The role of glucosylsphingosine as an early indicator of disease progression in early symptomatic type 1 Gaucher disease","volume":"27","author":"Stiles","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb1430","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043945","article-title":"Contribution of Glucosylsphingosine (Lyso-Gb1) to treatment decisions in patients with Gaucher disease","volume":"24","author":"Dinur","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.ymgme.2025.109074_bb1435","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20123033","article-title":"Glucosylsphingosine (lyso-Gb1) as a biomarker for monitoring treated and untreated children with Gaucher disease","volume":"20","author":"Hurvitz","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb1440","article-title":"Enzyme replacement and substrate reduction therapy for Gaucher disease","volume":"2015","author":"Shemesh","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ymgme.2025.109074_bb1445","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bcmd.2019.04.003","article-title":"Addendum to letter to the editor: safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1","volume":"77","author":"Mistry","year":"2019","journal-title":"Blood Cells Mol. Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb1450","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.23382","article-title":"Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease","volume":"88","author":"Ben Turkia","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb1455","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/10600280221108443","article-title":"A systematic review and Meta-analyses of longitudinal studies on drug treatments for Gaucher disease","volume":"57","author":"Leonart","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ymgme.2025.109074_bb1460","first-page":"12","article-title":"Osteonecrosis in Gaucher disease in the era of multiple therapies: biomarker set for risk stratification from a tertiary referral center","author":"Basiri","year":"2023","journal-title":"Elife"},{"issue":"14","key":"10.1016\/j.ymgme.2025.109074_bb1465","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147699","article-title":"Impact of long-term enzyme replacement therapy on Glucosylsphingosine (Lyso-Gb1) values in patients with type 1 Gaucher disease: statistical models for comparing three enzymatic formulations","volume":"22","author":"Dinur","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2025.109074_bb1470","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0049-3848(15)50443-X","article-title":"Management of women with Gaucher disease in the reproductive age","volume":"135","author":"Rosenbaum","year":"2015","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1475","first-page":"76","article-title":"Pregnancy outcome in women with Gaucher disease type 1 who had unplanned pregnancies during eliglustat clinical trials","volume":"57","author":"Lukina","year":"2021","journal-title":"JIMD Rep."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb1480","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ymgme.2019.11.002","article-title":"Impact of hepatic and renal impairment on the pharmacokinetics and tolerability of eliglustat therapy for Gaucher disease type 1","volume":"129","author":"Li","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109074_bb1485","author":"Sanofi"},{"key":"10.1016\/j.ymgme.2025.109074_bb1490","article-title":"Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease","volume":"29","author":"Kleytman","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109074_bb1495","first-page":"25","article-title":"Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: a sub-analysis of the eliglustat ENCORE trial","volume":"9","author":"Pleat","year":"2016","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"7","key":"10.1016\/j.ymgme.2025.109074_bb1500","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ajh.24007","article-title":"Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease","volume":"90","author":"Elstein","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2025.109074_bb1505","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2017.08.005","article-title":"Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naive and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: data from phase 3 clinical trials","volume":"122","author":"Elstein","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"21","key":"10.1016\/j.ymgme.2025.109074_bb1510","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11216265","article-title":"Real-life experience with Oral eliglustat in patients with Gaucher disease previously treated with enzyme replacement therapy","volume":"11","author":"Istaiti","year":"2022","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.ymgme.2025.109074_bb1515","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076732","article-title":"High-dose Ambroxol therapy in type 1 Gaucher disease focusing on patients with poor response to enzyme replacement therapy or substrate reduction therapy","volume":"24","author":"Istaiti","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.ymgme.2025.109074_bb1520","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11175158","article-title":"Switching between enzyme replacement therapies and substrate reduction therapies in patients with Gaucher disease: data from the Gaucher outcome survey (GOS)","volume":"11","author":"Hughes","year":"2022","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.ymgme.2025.109074_bb1525","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12124017","volume":"12","author":"Hughes","year":"2023","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.ymgme.2025.109074_bb1530","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12093269","volume":"12","author":"Mistry","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymgme.2025.109074_bb1535","article-title":"Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3","volume":"31","author":"Lee","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1540","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13256-016-1147-5","article-title":"Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report","volume":"11","author":"Ceravolo","year":"2017","journal-title":"J. Med. Case Rep."},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb1545","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10545-008-0873-2","article-title":"Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III","volume":"31","author":"Cox-Brinkman","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"issue":"7","key":"10.1016\/j.ymgme.2025.109074_bb1550","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1194\/jlr.R047167","article-title":"The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases","volume":"55","author":"Shayman","year":"2014","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1555","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0167-4838(87)90128-2","article-title":"Human acid beta-glucosidase: use of inhibitors, alternative substrates and amphiphiles to investigate the properties of the normal and Gaucher disease active sites","volume":"915","author":"Osiecki-Newman","year":"1987","journal-title":"Biochim. Biophys. Acta"},{"issue":"39","key":"10.1016\/j.ymgme.2025.109074_bb1560","doi-asserted-by":"crossref","first-page":"29052","DOI":"10.1074\/jbc.M705005200","article-title":"Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease","volume":"282","author":"Brumshtein","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb1565","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bcmd.2005.05.007","article-title":"Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations","volume":"35","author":"Alfonso","year":"2005","journal-title":"Blood Cells Mol. Dis."},{"issue":"24","key":"10.1016\/j.ymgme.2025.109074_bb1570","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.ymgme.2025.109074_bb1575","doi-asserted-by":"crossref","first-page":"43R","DOI":"10.1093\/glycob\/cwi076","article-title":"Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses","volume":"15","author":"Butters","year":"2005","journal-title":"Glycobiology"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb1580","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1021\/jm901281m","article-title":"Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation","volume":"53","author":"Wennekes","year":"2010","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ymgme.2025.109074_bb1585","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1310\/hpj5107-553","article-title":"Enzyme replacement or substrate reduction? A review of Gaucher disease treatment options","volume":"51","author":"Van Rossum","year":"2016","journal-title":"Hosp. Pharm."},{"issue":"7","key":"10.1016\/j.ymgme.2025.109074_bb1590","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1007\/s12325-024-02881-2","article-title":"Qualitative study of the patient experience with Venglustat for Gaucher disease type 3 in a phase 2 open-label, multicenter, multinational study (LEAP)","volume":"41","author":"Schiffmann","year":"2024","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ymgme.2025.109074_bb1595","author":"Takeda"},{"key":"10.1016\/j.ymgme.2025.109074_bb1600","author":"Pfizer"},{"key":"10.1016\/j.ymgme.2025.109074_bb1605","author":"Sanofi"},{"key":"10.1016\/j.ymgme.2025.109074_bb1610","author":"Janssen"},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1615","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1743-7075-10-34","article-title":"Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review","volume":"10","author":"Doneda","year":"2013","journal-title":"Nutr. Metab. (Lond.)"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb1620","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2015.05.012","article-title":"Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naive to enzyme replacement therapy or previously treated with imiglucerase","volume":"117","author":"Smith","year":"2016","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb1625","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ymgme.2015.09.002","article-title":"Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States","volume":"117","author":"Balwani","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109074_bb1630","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2019.112858","article-title":"Liquid chromatography-tandem mass spectrometric method for the quantification of eliglustat in rat plasma and the application in a pre-clinical study","volume":"177","author":"Chen","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ymgme.2025.109074_bb1635","series-title":"Medical Genetics Summaries","article-title":"Eliglustat therapy and CYP2D6 genotype","author":"Kane","year":"2020"},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb1640","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/cpt.2738","article-title":"Physiologically-based pharmacokinetic model development, validation, and application for prediction of eliglustat drug-drug interactions","volume":"112","author":"Sahasrabudhe","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2025.109074_bb1645","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bcmd.2016.03.004","article-title":"Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease","volume":"59","author":"Pastores","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb1650","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","article-title":"The long-term international safety experience of imiglucerase therapy for Gaucher disease","volume":"90","author":"Starzyk","year":"2007","journal-title":"Mol. Genet. Metab."},{"issue":"7","key":"10.1016\/j.ymgme.2025.109074_bb1655","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ajh.24369","article-title":"Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naive patients with Gaucher disease","volume":"91","author":"Zimran","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.ymgme.2025.109074_bb1660","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.anai.2020.07.010","article-title":"Management of hypersensitivity reactions to enzyme replacement therapy in children with lysosomal storage diseases","volume":"125","author":"Turgay Yagmur","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1665","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood.V90.1.43.43_43_48","article-title":"Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase","volume":"90","author":"Ponce","year":"1997","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ymgme.2025.109074_bb1670","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1542\/peds.100.6.e11","article-title":"Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease","volume":"100","author":"Brady","year":"1997","journal-title":"Pediatrics"},{"issue":"19","key":"10.1016\/j.ymgme.2025.109074_bb1675","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197159","article-title":"Value of Glucosylsphingosine (Lyso-Gb1) as a biomarker in Gaucher disease: a systematic literature review","volume":"21","author":"Revel-Vilk","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1680","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13023-023-02623-7","article-title":"Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review","volume":"18","author":"Giuffrida","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"issue":"13","key":"10.1016\/j.ymgme.2025.109074_bb1685","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21134577","article-title":"Treatment efficiency in Gaucher patients can reliably be monitored by quantification of Lyso-Gb1 concentrations in dried blood spots","volume":"21","author":"Cozma","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.ymgme.2025.109074_bb1690","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314938","article-title":"Glucosylsphingosine (Lyso-Gb(1)): an informative biomarker in the clinical monitoring of patients with Gaucher disease","volume":"23","author":"Gayed","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1695","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2021-000108","article-title":"Chronic pain and infection: mechanisms, causes, conditions, treatments, and controversies","volume":"1","author":"Cohen","year":"2022","journal-title":"BMJ Med."},{"issue":"1","key":"10.1016\/j.ymgme.2025.109074_bb1700","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13023-016-0435-x","article-title":"Rethinking fatigue in Gaucher disease","volume":"11","author":"Zion","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2025.109074_bb1705","first-page":"274","article-title":"Pharmacotherapy of Gaucher disease: current and future options","volume":"43","author":"Bennett","year":"2018","journal-title":"P T"},{"issue":"2","key":"10.1016\/j.ymgme.2025.109074_bb1710","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.106991","volume":"128","author":"Adera","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109074_bb1715","author":"Stansfield"},{"key":"10.1016\/j.ymgme.2025.109074_bb1720","author":"Packgene"},{"issue":"3","key":"10.1016\/j.ymgme.2025.109074_bb1725","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ymgme.2011.12.010","article-title":"Progressive mesenteric lymphadenopathy with protein-losing enteropathy; a devastating complication in Gaucher disease","volume":"105","author":"Lee","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109074_bb1730","first-page":"13","article-title":"Successful therapy for protein-losing enteropathy caused by chronic neuronopathic Gaucher disease","volume":"6","author":"Mhanni","year":"2016","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"25","key":"10.1016\/j.ymgme.2025.109074_bb1735","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1161\/CIRCULATIONAHA.105.598987","article-title":"Vascular biomarkers and surrogates in cardiovascular disease","volume":"113","author":"Tardif","year":"2006","journal-title":"Circulation"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225000654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225000654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T03:38:12Z","timestamp":1771558692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719225000654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":347,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1096719225000654"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109074","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in Gaucher disease: Perspectives from an expert panel","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109074"}}